Transcutaneous Vagus Nerve Stimulation (tVNS) for Improved Recovery After Exertion in Patients With Long/Post-COVID.
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 120
- 试验地点
- 3
- 主要终点
- Stimulation-induced changes in symptoms of depression
研究概览
简要总结
Widespread infection with SARS-CoV-2 has resulted in millions of people having Post-COVID. Post-COVID is a complex, non-monolithic disease with diverse clinical manifestations. Symptoms range from fatigue, brain fog, muscle aches and shortness of breath, affecting multiple organ systems simultaneously. To directly address this multi-organ component of Post-COVID, innovative treatment methods are urgently needed. One potential treatment that we will investigate in our study, is the intervention via the vagus nerve, as the cranial nerve plays a central role in communication between the body and the brain and influences targeted behavior. This innovative approach is based on our clinically relevant findings regarding the effects where acute tVNS increased the level of effort (Neuser et al., 2020; Ferstl et al., 2021), specifically targeting a key symptom of Post-COVID. In the proposed study, the investigators aim to investigate the effectiveness of transcutaneous vagus nerve stimulation (tVNS) as a non-invasive, self-administered treatment for Post-COVID symptoms at home. To evaluate the clinically relevant effects of repeated taVNS application (high-intensity stimulation), the investigators will employ a randomized cross-over design to investigate stimulation-induced changes in fatigue, depression and motivation to work for reward compared to low-intensity stimulation and to a control group.
详细描述
The proposed study aims to advance the understanding of Post-COVID treatment using a randomized cross-over design to evaluate the taVNS-induced changes over 12 weeks. A hundred twenty patients diagnosed with Long/Post-COVID are randomly assigned to one of three groups related to the two arms of the study ("Monitoring with low/high-intensity stimulation" vs. Monitoring without stimulation"). In the treatment group, forty patients will start with high-intensity taVNS for 6 weeks, then switch to low-intensity stimulation for an additional 6 weeks. Another 40 patients begin with low-intensity stimulation for 6 weeks, followed by high-intensity taVNS stimulation. The control group ("Monitoring without stimulation") is able to receive taVNS after participation in the study.
The treatment group and the control group will participate in the same monitoring procedures. All participants will attend an initial laboratory session to complete several baseline assessments, including questionnaires, measuring energy expenditure via indirect calorimetry and completing a body silhouette task. Blood samples are taken at every session to evaluate changes in metabolic and inflammatory markers. To assess the motivation to work for rewards, the investigators employ an effort-based-cost-benefit paradigm (Effort Allocation Task). All these lab assessments will be repeated after 6 and 12 weeks to evaluate stimulation-induces changes in primary and secondary outcomes. In addition, all participants are given a cardio bracelet to monitor physiological parameters (e.g. heart rate, heart rate variability, breathing, skin conductance, step counts) over the study period. Over the 12 weeks, the treatment group will self-administer taVNS for four hours daily in a targeted manner, anticipating forthcoming exertion and stimulating in anticipation of an effortful event to enhance the patients' motivational drive and recovery. Another essential part of the study is the monitoring over the 12 weeks. All participants will complete daily ecological momentary assessments via smartphone to monitor their mental states. In addition, participants will perform once a day one of two discounting games (effort or temporal discounting task) to investigate changes in their decision behavior over time. The effort discounting task is essential to assess the motivation of post-COVID patients to pursue subjectively effortful situations over the 12 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •individuals who have previously tested positive for SARS-CoV-2 infection (preferred PCR-Test) or have a medically confirmed history of COVID-19 (preferred SARS-CoV-2 Antibody-test) and have persistent symptoms (including Post-COVID) .
- •clinical diagnoses made by physician: individuals are included with at least one persistent symptom for at least 4 weeks (Long-COVID) or at least 8 weeks (Post-COVID) following the SARS-CoV-2 infections, such as fatigue, shortness of breath, brain fog, headaches, irritability, cognitive difficulties, muscle or joint pain, sleep disturbances, etc.
- •Participants should not have an alternative explanation for their persistent symptoms, ruling out other medical or psychiatric conditions.
排除标准
- •lack of capacity for consent
- •insufficient German language skills: Participants must have sufficient (B2 German) language skills to understand the informed consent form, study procedures, and questionnaires.
- •Intensive Care Unit treatment during COVID-19 infection
- •BMI > 18.5 & BMI < 30 kg/m2
- •Lifetime (according to DSM 5):
- •brain injury, stroke, epilepsy, or history of seizures
- •schizophrenia
- •bipolar disorder
- •severe substance use disorders, except tobacco
- •cardiac arrhythmia, coronary heart disease
- •12-month prevalence: pregnancy or nursing
- •Additional exclusion criteria for a safe application of tVNS:
- •active implant (pacemaker, cochlear implant, implanted electrode device) and cerebral shunts
- •required permanent use of left-sided hearing aid
- •ear infections, open wounds, or impaired skin at electrode sites
研究组 & 干预措施
Monitoring with high/low-intensity stimulation
The cross-over design includes one group which starts with high-intensity stimulation (n = 40) and another group, who starts with low-intensity stimulation (n = 40). The first group receives at first high-intensity for 6 weeks, followed by a low-intensity stimulation phase for 6 weeks. To control for placebo effects, other forty individuals start with the 6-week low-intensity stimulation phase followed by 6 weeks of high-intensity tVNS stimulation phase.
干预措施: Monitoring (Behavioral)
Monitoring with high/low-intensity stimulation
The cross-over design includes one group which starts with high-intensity stimulation (n = 40) and another group, who starts with low-intensity stimulation (n = 40). The first group receives at first high-intensity for 6 weeks, followed by a low-intensity stimulation phase for 6 weeks. To control for placebo effects, other forty individuals start with the 6-week low-intensity stimulation phase followed by 6 weeks of high-intensity tVNS stimulation phase.
干预措施: cardiowatch bracelet (Device)
Monitoring without stimulation
Another group of patients is included as a control group (n = 40) undergoing 'treatment as usual' for Long/Post Covid. This group of participants receive the same monitoring throughout their participation during 12 weeks as the Stimulation-Group. As there is no standardized treatment protocol for Long/Post Covid, 'treatment as usual' implies a supportive approach.
This group of participants have the option to receive taVNS stimulation after participating in the study.
干预措施: cardiowatch bracelet (Device)
Monitoring with high/low-intensity stimulation
The cross-over design includes one group which starts with high-intensity stimulation (n = 40) and another group, who starts with low-intensity stimulation (n = 40). The first group receives at first high-intensity for 6 weeks, followed by a low-intensity stimulation phase for 6 weeks. To control for placebo effects, other forty individuals start with the 6-week low-intensity stimulation phase followed by 6 weeks of high-intensity tVNS stimulation phase.
干预措施: transcutaneous vagus nerve stimulation (Device)
Monitoring without stimulation
Another group of patients is included as a control group (n = 40) undergoing 'treatment as usual' for Long/Post Covid. This group of participants receive the same monitoring throughout their participation during 12 weeks as the Stimulation-Group. As there is no standardized treatment protocol for Long/Post Covid, 'treatment as usual' implies a supportive approach.
This group of participants have the option to receive taVNS stimulation after participating in the study.
干预措施: Monitoring (Behavioral)
结局指标
主要结局
Stimulation-induced changes in symptoms of depression
时间窗: Pre treatment vs. after 6-week tVNS vs. after 6-week low-intensity stimulation phase
Changes in symptoms of depression are measured via the Montgomery Asberg Depression Scale. The MADRS comprises 10 items rated on a scale from 0 to 6 to compute a sum score with higher scores indicating severe symptoms of depression.
Stimulation-induced changes in invigoration: frequency of button presses during the first seconds of the trial to gain monetary rewards in the Effort Allocation Task.
时间窗: Pre treatment vs. after 6-week tVNS vs. after 6-week low-intensity stimulation phase
Changes in invigoration to work for rewards are operationalized as the relative increase in the frequency of button presses on an Xbox controller during the first seconds of the trial in the Effort Allocation Task.
Stimulation-induced changes in physical and mental aspects of fatigue
时间窗: Pre treatment vs. after 6-week tVNS vs. after 6-week low-intensity stimulation phase
Changes in fatigue are measured by the Chalder Fatigue scale. The CFS comprises 11 questions rated on a 4-point Likert scale to compute a sum score. It will be measured three times six weeks apart.
次要结局
- Stimulation-induced changes in heart rate variability(during 6-week tVNS compared to during 6-week low-intensity stimulation phase)
- Stimulation-induced changes in wanting the monetary rewards(Pre treatment vs. after 6-week tVNS vs. after 6-week low-intensity stimulation phase)
- Stimulation-induced changes in the motivation to invest effort: the discounting rate reflecting rewards devalued by effort(during 6-week tVNS compared to during 6-week low-intensity stimulation phase)
- Stimulation-induced changes in mood(Pre treatment vs. after 6-week tVNS vs. after 6-week low-intensity stimulation phase)
- Stimulation-induced changes in metabolic and inflammatory markers(Pre treatment vs. after 6-week tVNS vs. after 6-week low-intensity stimulation phase)
- Stimulation-induced changes in heart rate(during 6-week tVNS compared to during 6-week low-intensity stimulation phase)
- Stimulation-induced changes in exertion(Pre treatment vs. after 6-week tVNS vs. after 6-week low-intensity stimulation phase)
- Stimulation-induced changes in health-related quality of life(Pre treatment vs. after 6-week tVNS vs. after 6-week low-intensity stimulation phase)
- Stimulation-induced changes in physical activity(during 6-week tVNS compared to during 6-week low-intensity stimulation phase)
- Stimulation-induced changes in resting energy expenditure(Pre treatment vs. after 6-week tVNS vs. after 6-week low-intensity stimulation phase)
- Stimulation-induced changes in maintenance:the average relative frequency across the complete trial to gain monetary rewards in the Effort Allocation Task.(Pre treatment vs. after 6-week tVNS vs. after 6-week low-intensity stimulation phase)
- Stimulation-induced changes in mood and mood response to effort(Pre treatment vs. after 6-week tVNS vs. after 6-week low-intensity stimulation phase)
- Stimulation-induced changes in effort utility(Pre-treatment vs. after 6-week tVNS vs. after 6-week low-intensity stimulation phase)
- stimulation-induced changes in self-reported depressive symptoms(Pre treatment vs. after 6-week tVNS vs. after 6-week low-intensity stimulation phase)
- Stimulation-induced changes in HR(During 6-week tVNS compared to during 6-week low-intensity stimulation phase)